Press Releases

DAY HI:
DAY LOW:
VOLUME:

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases

Date Title Format
Sep 27, 2018
HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 27, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business
Sep 24, 2018
Data were featured in an oral presentation at the IASLC 19th World Conference on Lung Cancer Spectrum will host a live webcast today at 4:30 p.m. Eastern/1:30 p.m. Pacific HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 24, 2018-- Spectrum Pharmaceuticals, Inc.
Sep 12, 2018

Spectrum’s Phase 2 non-small cell lung cancer (NSCLC) study expanded to include two new cohorts for first-line NSCLC patients with EGFR or HER2 exon 20 insertion mutations Phase 2 study now includes four cohorts with each cohort being an independent study with pre-specified statistical hypotheses

Sep 05, 2018

The abstract reported new interim data from the EGFR cohort and, for the first time, the HER2 cohort in the MD Anderson Phase 2 trial In the EGFR cohort, an objective response rate of 58% and a disease control rate of 90% were reported In the HER2 cohort, an objective response rate of 50% and a

Aug 30, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 30, 2018-- Spectrum Pharmaceuticals, Inc.  (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business

Aug 09, 2018

An oral presentation of updated Phase 2 poziotinib data including EGFR and HER2 patients with exon 20 mutations will occur on September 24 at the World Conference on Lung Cancer in Toronto Spectrum’s current poziotinib Phase 2 study is viewed as the pivotal registrational trial following recent

Aug 02, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 2, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with

Jun 29, 2018

ADVANCE, first Phase 3 study, met the non-inferiority of ROLONTIS to pegfilgrastim endpoint in the Duration of Severe Neutropenia (DSN) across all 4 cycles (all p

Jun 25, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 25, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the company will hold a conference call on Friday,

May 30, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--May 30, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy

May 16, 2018

Primary endpoint of non-inferiority of ROLONTIS to pegfilgrastim was met All secondary endpoints were met Adverse events were similar between ROLONTIS and pegfilgrastim ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) that utilizes a propriety technology HENDERSON,

May 09, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--May 9, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company’s business strategy

May 03, 2018

Enrollment completed in MD Anderson’s 50 patient EGFR exon 20 mutation cohort for poziotinib in non-small cell lung cancer. Nature Medicine publication reported a confirmed objective response rate of 64 percent in the first 11 patients with EGFR exon 20 mutations treated with poziotinib.

May 03, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--May 3, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today an exclusive licensing agreement with The

May 01, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--May 1, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it has entered into an agreement with Thermo

Apr 30, 2018

Shareholder Rights Plan Amended to Eliminate Poison Pill Bylaws Amended to Enable Proxy Access and Majority Voting Dr. Bernice R. Welles Recommended to be Added to Spectrum’s Board of Directors HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 30, 2018-- Spectrum Pharmaceuticals, Inc.

Apr 27, 2018

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology. Spectrum currently markets six hematology/oncology drugs, and has an advanced stage pipeline that has the potential to

Apr 26, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 26, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with

Apr 23, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 23, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced a publication entitled, “Mechanisms and

Apr 17, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 17, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced a poster presentation of data from preclinical and

Displaying 21 - 40 of 773